Zacks: Analysts Anticipate MEI Pharma, Inc. (NASDAQ:MEIP) Will Post Earnings of -$0.07 Per Share


Share on StockTwits

Equities analysts expect that MEI Pharma, Inc. (NASDAQ:MEIP) will report earnings of ($0.07) per share for the current quarter, according to Zacks. Three analysts have issued estimates for MEI Pharma’s earnings. MEI Pharma posted earnings per share of ($0.15) during the same quarter last year, which would indicate a positive year over year growth rate of 53.3%. The firm is scheduled to announce its next quarterly earnings report on Thursday, February 4th.

On average, analysts expect that MEI Pharma will report full-year earnings of ($0.51) per share for the current financial year, with EPS estimates ranging from ($0.65) to ($0.42). For the next financial year, analysts expect that the company will report earnings of ($0.52) per share, with EPS estimates ranging from ($0.79) to ($0.26). Zacks Investment Research’s EPS averages are a mean average based on a survey of analysts that that provide coverage for MEI Pharma.

MEI Pharma (NASDAQ:MEIP) last posted its quarterly earnings data on Tuesday, November 10th. The company reported ($0.25) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.07) by ($0.18). MEI Pharma had a negative net margin of 142.81% and a negative return on equity of 33.55%. The company had revenue of $3.83 million for the quarter, compared to the consensus estimate of $2.48 million.

A number of brokerages recently weighed in on MEIP. Lifesci Capital reissued an “outperform” rating on shares of MEI Pharma in a report on Wednesday, October 21st. Brookline Capital Management reiterated a “buy” rating on shares of MEI Pharma in a research report on Monday, October 12th. ValuEngine upgraded MEI Pharma from a “hold” rating to a “buy” rating in a research note on Friday, November 13th. Zacks Investment Research cut MEI Pharma from a “hold” rating to a “sell” rating in a research note on Thursday, September 10th. Finally, Alliance Global Partners initiated coverage on MEI Pharma in a research note on Tuesday, September 22nd. They issued a “buy” rating and a $9.00 target price for the company. One analyst has rated the stock with a sell rating, two have given a hold rating and seven have assigned a buy rating to the company. MEI Pharma has a consensus rating of “Buy” and a consensus target price of $9.29.

NASDAQ MEIP opened at $2.64 on Wednesday. The company’s fifty day moving average price is $2.87 and its two-hundred day moving average price is $3.04. MEI Pharma has a 12 month low of $0.72 and a 12 month high of $4.46. The company has a market capitalization of $297.06 million, a price-to-earnings ratio of -4.40 and a beta of 1.71.

Several large investors have recently made changes to their positions in the company. Bank of Montreal Can bought a new position in shares of MEI Pharma in the 2nd quarter worth $28,000. State of Wisconsin Investment Board purchased a new stake in MEI Pharma in the 2nd quarter worth approximately $44,000. Brooks Moore & Associates Inc. bought a new stake in MEI Pharma during the 3rd quarter worth approximately $34,000. Private Advisor Group LLC purchased a new position in MEI Pharma during the second quarter valued at approximately $53,000. Finally, HighMark Wealth Management LLC bought a new position in shares of MEI Pharma in the third quarter worth approximately $52,000. 54.58% of the stock is currently owned by institutional investors.

MEI Pharma Company Profile

MEI Pharma, Inc, a late-stage pharmaceutical company, focuses on the development of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor that is in Phase II clinical trial for the treatment of patients with relapsed/refractory follicular lymphoma, as well as in Phase Ib multi-arm trial to treat B-cell malignancies; and Voruciclib, an oral cyclin-dependent kinase inhibitor, which is in Phase Ib clinical trial for acute myeloid leukemia and B-cell malignancies.

Featured Article: Dual Listing

Get a free copy of the Zacks research report on MEI Pharma (MEIP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for MEI Pharma (NASDAQ:MEIP)

Receive News & Ratings for MEI Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MEI Pharma and related companies with MarketBeat.com's FREE daily email newsletter.